Skip to content
value.today

Vogenx, Inc.

VOGX
$296 Mmarket cap on Oct 30, 2026
Compare
World rank
#14,848
Revenue
—
annual
Net income
—
Employees
—

Vogenx, Inc. in brief

Vogenx, Inc. is a listed company in the Biotechnology industry, based in Raleigh, North Carolina, USA. Its market value was $296 M on 30 October 2026, which makes it the 14,848th largest listed company in the world and the 2,889th largest in the USA on this site. James Green is its chief executive. Its shares trade under the symbol VOGX (Nasdaq).

Written from the figures on this page, so it changes when they do. Dates and sources are under Sources and freshness.

Vogenx, Inc. timeline

2 events, 2026
  1. 2026
  2. •
    · approximate
    First filing with the US SEC
    The company's first electronic filing in SEC EDGAR.
  3. 🔔
    Initial public offering on Nasdaq
    Final prospectus filed with the SEC on 12 August 2026; shares registered for exchange trading on 10 August 2026.

Events of Vogenx, Inc. from SEC EDGAR. Dates marked approximate come from statements without a cited source. Spotted a mistake? Use the correction form below.

Market cap history

$0 M$80 M$160 M$240 M$320 M

World rank over time

▲ up 256 places since 2026
2026-08-01: #15138#15,13820262026-10-14: #15578#15,57820262026-10-30: #14882#14,8822026

Rank in USA: #3,051 (Aug 2026) · #3,012 (Oct 2026) · #2,893 (Oct 2026)

Quarterly results

USD · three months to · source: SEC filings
RevenueNet income
Three months to Mar 2025: revenue —, net income $-0M—Mar ’25Three months to Jun 2025: revenue —, net income $-0M—Jun ’25Three months to Sep 2025: revenue —, net income $-0M—Sep ’25Three months to Mar 2026: revenue —, net income $-0M—Mar ’26Three months to Jun 2026: revenue —, net income $-0M—Jun ’26Three months to Sep 2026: revenue —, net income $-5M—Sep ’26

Latest quarter to Sep 2026: revenue —, net income $-5M.

SEC filings

Official filings of Vogenx, Inc. with the US Securities and Exchange Commission.

Balance sheet

Total assets
$1 M
Total liabilities
$2 M
Total equity
$-1 M

As of December-2025

Top 30 institutional investors in Vogenx, Inc.#

As of Sep 30, 2026
30 institutions held 7.9 M shares (about 53.0% of the shares outstanding) on Sep 30, 2026. The ten largest hold 47.4%. Source: SEC Form 13F filings, filed through Nov 16, 2026. Change is since the previous quarter.This quarter is still being filed: about 99% of the institutions that reported last quarter have filed so far. Institutions that have not filed yet are missing from the list, not sellers; the list is brought up to date every day.
The 25 largest institutional investors in Vogenx, Inc.
#InstitutionShares heldChange (shares)% heldValueFiled
1Janus Henderson Group Ltd.1,923,076—12.95%$44 MNov 16, 2026
2Orbimed Advisors LLC968,621New6.52%$22 MNov 16, 2026
3Affinity Asset Advisors, LLC915,000New6.16%$21 MNov 13, 2026
4Adage Capital Partners GP, L.L.C.800,000New5.39%$18 MNov 16, 2026
5Deerfield Management Company, L.P.635,707New4.28%$14 MNov 16, 2026
6Longbow Finance SA600,202New4.04%$14 MNov 13, 2026
7ADAR1 Capital Management, LLC522,175New3.52%$12 MNov 16, 2026
8AWM Investment Company, Inc.258,651New1.74%$6 MNov 13, 2026
9Acuta Capital Partners, LLC213,186New1.44%$5 MNov 16, 2026
10Ikarian Capital, LLC208,836New1.41%$5 MNov 16, 2026
11Logos Global Management LP205,000New1.38%$5 MNov 16, 2026
12BlackRock, Inc.97,205New0.65%$2 MNov 13, 2026
13KVP Capital Advisors, LP86,069New0.58%$2 MNov 16, 2026
14Geode Capital Management, LLC77,334New0.52%$2 MNov 6, 2026
15Vanguard Capital Management LLC71,029New0.48%$2 MNov 13, 2026
16Millennium Management LLC65,864New0.44%$2 MNov 16, 2026
17Boothbay Fund Management, LLC60,929New0.41%$1 MNov 16, 2026
18Vanguard Fiduciary Trust Co34,632New0.23%$1 MNov 13, 2026
19Ally Bridge Group (NY) LLC32,701New0.22%$1 MNov 16, 2026
20Hudson Bay Capital Management LP21,290New0.14%$0 MNov 13, 2026
21Marshall Wace, LLP19,110New0.13%$0 MNov 13, 2026
22State Street Corp14,250New0.10%$0 MNov 12, 2026
23Northern Trust Corp14,032New0.09%$0 MNov 16, 2026
24Goldman Sachs Group Inc12,454New0.08%$0 MNov 16, 2026
25UBS Group AG9,937New0.07%$0 MNov 10, 2026
Show all 30: investors 26 to 30
Institutional investors 26 to 30 in Vogenx, Inc.
#InstitutionShares heldChange (shares)% heldValueFiled
26Vanguard Portfolio Management LLC6,062New0.04%$0 MNov 13, 2026
27Aster Capital Management (DIFC) Ltd3,125New0.02%$0 MNov 12, 2026
28Vanguard Global Advisers, LLC2,425New0.02%$0 MNov 13, 2026
29Citigroup Inc952New0.01%$0 MNov 4, 2026
30Morgan Stanley236New0.00%$0 MNov 13, 2026

Insider trading at Vogenx, Inc.#

Shares bought and sold by directors, officers and 10% owners, from their SEC Form 4 filings.

Bought, 12 months
$0
0 purchases, 0 insiders
Sold, 12 months
$0
0 sales, 0 insiders
Net, 12 months
$0
open market only
Insiders on file
2
since
Vogenx, Inc.: latest insider trades
TradedInsiderTradeSharesPriceValueOwned afterFiling
filed Steven R. DelmarChief Financial Officer, DirectorConversion+4,273$11.70$50 K704,273Form 4
filed Peter PieracciniDirectorConversionindirect+42,735$11.70$500 K42,735Form 4

Source: SEC Forms 4 and 5. Awards, option exercises and shares withheld for tax are listed but not counted in the totals

Markets and events: Vogenx, Inc.#

Short interest, dividends, buybacks, splits, index changes and other events from FINRA, the SEC and the exchanges.

Short interest, 2026-10-30
74,122
1 days to cover
Shares sold short, last 6 reportsAll stocks →

IPO: priced at $13.00, raising $81.3M · IPO calendar

Trading halts

  • 2026-08-14 13:32 UTC, code LUDP, resumed 13:37 UTC

Fails to deliver

  • : 674 shares at $19.92
  • : 2,375 shares at $18.92
  • : 3,817 shares at $19.08
  • : 6,916 shares at $20.39
  • : 2,394 shares at $18.75

Source: FINRA, SEC EDGAR (8-K, S-1/F-1, 424B4, XBRL, fails-to-deliver), Nasdaq Trader, Wikipedia index change tables

Vogenx, Inc. scorecard#

Passes 0 of the 2 checks that could be worked out. Fiscal year 2025; market cap of Oct 30, 2026.

  • Valuation0 of 1
    • –P/E below its peers' medianNo P/E on file.
    • ✗Price to book below its peers' medianNo price to bookShareholders' equity is negative.
    • –Price to sales below its peers' medianNo Price to sales on file.
    • –Free cash flow yield above 5%No free cash flow yield on file.
    • –Earnings yield above the 10-year Treasury yieldNo P/E on file.
    • –The price assumes slower growth than the last three years'Free cash flow of the last three years is missing or below zero on average.
  • Growthnot known
    • –Revenue grew in the newest yearRevenue of the year before is not on file.
    • –Revenue up more than 5% a year over three yearsRevenue of three years earlier is not on file.
    • –Faster growth over three years than its peers' medianRevenue of three years earlier is not on file.
    • –Earnings per share grew in the newest yearEarnings per share of two years are not on file.
    • –Net income higher than five years earlierNet income of five years earlier is not on file.
    • –Revenue rose in at least four of the last five yearsFive years of revenue changes are not on file.
  • Profitabilitynot known
    • –Profitable in the newest yearNo net income on file.
    • –Profitable in each of the last five yearsFive years of net income are not on file.
    • –Operating margin above its peers' medianNo operating margin on file.
    • –Return on equity above 15%No return on equity (equity missing or negative).
    • –Return on invested capital above 10%No return on invested capital on file.
    • –Operating margin wider than three years earlierOperating margins of three years earlier are not on file.
  • Financial health0 of 1
    • ✗Short-term assets cover short-term liabilities0.4×Current ratio 0.42 at the end of fiscal 2025.
    • –Debt below equityDebt or equity is not on file (or equity is negative).
    • –Net debt below three years of EBITDANet debt to EBITDA is not on file.
    • –Operating income covers interest five timesInterest expense is not on file.
    • –Cash from operations positive in each of the last three yearsThree years of operating cash flow are not on file.
    • –Altman Z-score outside the distress zoneThe Z-score's figures are not all on file.
  • Shareholder returnsnot known
    • –Pays a dividendDividends are not on file.
    • –Dividend per share raised five years in a rowSix years of dividends per share are not on file.
    • –Dividends under 75% of net incomePays no dividend (or dividends are not on file).
    • –Share count up no more than 2% in a yearShare counts of two years are not on file.
    • –Dividends and buybacks above 3% of the market valueDividends and buybacks are not on file.
    • –Free cash flow covers dividends and buybacksCash from operations or capital spending is not on file.

Worked out from the statements as filed (sec), the medians of Biotechnology, the 10-year Treasury yield of Nov 13, 2026 and the market cap. A check that cannot be worked out counts neither way. A reading aid, not advice. How the checks work

Events at Vogenx, Inc.#

What the company reported to the SEC within four business days (Form 8-K), newest first.

No warning signs in the last three years: no bankruptcy, delisting notice, withdrawn financial statements, auditor change, cybersecurity incident, debt called early or impairment was reported.

Directors and officers 2 · Bylaws or fiscal year changed 1 · Results announced 1

Vogenx, Inc.: events reported to the SEC
FiledWhat happenedFiling
Results announced8-K
Directors and officers8-K
Directors and officers8-K
Bylaws or fiscal year changed8-K

Source: SEC EDGAR, Form 8-K item numbers · as of Nov 6, 2026

How Vogenx, Inc. compares in Biotechnology

  • Market cap$296 M · higher than 51% of 726

Peer comparison · Biotechnology

CompanyMarket capP/ENet marginRev. growth
Vogenx, Inc.🇺🇸$296 M———
Novo Nordisk A/S🇩🇰$203.2 B13.1×33.1%+10.8%
Vertex Pharmaceuticals Incorporated🇺🇸$134.3 B33.8×30.7%+8.9%
Moderna, Inc.🇺🇸$90.1 B—-110.5%-39.9%
Regeneron Pharmaceuticals, Inc.🇺🇸$84.1 B17.5×28.5%+1.0%
Argenx SE🇳🇱$52.8 B40.9×31.1%+89.9%
CSL Limited🇦🇺$51.6 B—-16.4%—
Samsung Biologics Co., Ltd.🇰🇷$51.5 B40.5×39.2%—
UCB SA🇧🇪$48.6 B26.3×20.1%+31.1%

P/E and margins use trailing 12-month results where available; growth is the latest fiscal year.

Questions, comparisons and similar companies#

Sources and freshness

Market cap:
Oct 30, 2026
Balance sheet:
As of December-2025
Profile updated:
Nov 20, 2026

Figures from Market data, SEC filing, value.today research; financial statements from SEC filings.

How each figure is collected: data sources and methodology. Market caps in US dollars unless you switch the currency.

Work at Vogenx, Inc.? Verify and update this profile — free

Use your work e-mail address (on the company's own domain if possible). Fill in only what is new or missing; a link to where the figures are published (annual report, press release) speeds up the review.

Show Vogenx, Inc.'s ranking on your website Get the badge
Badge preview

The badge updates itself as the ranking changes.

Something wrong or missing about Vogenx, Inc.? Suggest a correction